-$0.01 EPS Expected for Kitov Pharmaceuticals Holdings Ltd (KTOV) This Quarter

Wall Street analysts expect that Kitov Pharmaceuticals Holdings Ltd (NASDAQ:KTOV) will post ($0.01) earnings per share for the current fiscal quarter, Zacks Investment Research reports. Zero analysts have issued estimates for Kitov Pharmaceuticals’ earnings. The company is expected to announce its next earnings report on Monday, May 7th.

According to Zacks, analysts expect that Kitov Pharmaceuticals will report full-year earnings of ($0.01) per share for the current financial year. Zacks’ earnings per share calculations are a mean average based on a survey of sell-side analysts that follow Kitov Pharmaceuticals.

Separately, HC Wainwright raised Kitov Pharmaceuticals from a “neutral” rating to a “buy” rating and set a $10.00 price objective on the stock in a report on Tuesday, November 21st.

Shares of Kitov Pharmaceuticals (NASDAQ KTOV) opened at $2.29 on Friday. Kitov Pharmaceuticals has a 1-year low of $1.27 and a 1-year high of $3.49.

WARNING: “-$0.01 EPS Expected for Kitov Pharmaceuticals Holdings Ltd (KTOV) This Quarter” was originally posted by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are viewing this article on another domain, it was illegally stolen and republished in violation of international copyright & trademark legislation. The original version of this article can be accessed at https://www.dispatchtribunal.com/2018/01/12/0-01-eps-expected-for-kitov-pharmaceuticals-holdings-ltd-ktov-this-quarter.html.

About Kitov Pharmaceuticals

Kitov Pharmaceuticals Holdings Ltd is an Israel-based company that develops non-steroidal anti-inflammatory drugs that treat pain without raising blood pressure, thus avoiding the increased risk of heart attacks, strokes or death.

Get a free copy of the Zacks research report on Kitov Pharmaceuticals (KTOV)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Kitov Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kitov Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply